1. Introduction {#s0005}
===============

Alzheimer\'s disease (AD), the most common form of dementia, affects 11% of individuals over age 65 worldwide with no known cure. Although memory loss is the primary symptom, AD patients manifest heterogeneous cognitive profiles, i.e., each individual could express different extents of decline in memory, executive skills, language, and perceptuospatial abilities ([@bb0240]; [@bb0275]; [@bb0265]), which complicate the diagnosis. Hence, there is a pressing need to identify AD subtypes for improving diagnosis accuracy and monitor disease progression.

AD is a complex neurodegenerative disease in that pathological and structural heterogeneity is constantly observed in AD ([@bb0160]; [@bb0090]; [@bb0145]; [@bb0055]; [@bb0280]; [@bb0110]). For example, neuropathological studies found that 25--30% of the AD cases had untypical distributions of amyloid plaques and neurofibrillary tangles (NFTs), and exhibited different rates of disease progression compared with typical AD cases ([@bb0200]; [@bb0210]; [@bb0290]). MRI studies reported that 10--30% of the AD patients exhibited untypical hippocampal atrophy ([@bb0105]; [@bb0235]; [@bb0175]). Moreover, a recent MRI study suggested that the varying patterns of the whole brain gray matter (GM) atrophy were associated with distinct trajectories of multidomain cognitive decline in AD ([@bb0310]; [@bb0205]; [@bb0215]).

White matter (WM) impairment also contributes to AD pathology ([@bb0225]; [@bb0015]) and can be detected even before the development of cortical atrophy in at-risk and heathy participants ([@bb0015]; [@bb0185]). Most WM studies on AD assumed a single disease effect that charts only the overall associations between WM changes and cognition decline in AD ([@bb0010]; [@bb0045]). One study reported that WM impairment in AD was associated with impairment in different cognitive domains ([@bb0125]). A recent study assessed WM impairment in typical and atypical AD and identified syndrome-specific patterns of WM microstructure breakdown ([@bb0070]). Inspired by these findings, we hypothesize that heterogeneity exists in WM impairment in AD, which could explain the variations of multidomain cognitive decline among participants across the disease spectrum.

In this work, we explored the heterogeneity of WM impairment in AD by using Latent Dirichlet Allocation (LDA) to identify multiple latent disease factors from WM skeletons constructed using diffusion tensor imaging (DTI) data ([@bb0310]; [@bb0040]). LDA provides a probabilistic description of multiple impairment factors. For example, concerning patient A, the WM impairment pattern might be 70% owing to factor 1 and 30% to factor 2; while concerning patient B, the impairment might be 20% owing to factor 1 and 80% to factor 2. It remains an open question whether subtypes, which manifest heterogeneity in AD cases, are exclusive or mixing up in an individual. LDA explores the mixed effects of multiple latent factors in a probabilistic framework and is therefore well suited for studying heterogeneity in AD.

AD develops slowly from a preclinical phase and the pathophysiological changes start about a decade before the final diagnosis ([@bb0285]). In this work, we found that heterogeneity of WM impairment already appears before clinical syndromes are fully expressed. We revealed the association between the WM impairment factors and the cognitive decline in participants throughout the disease spectrum. In addition, we verified that the genotype was associated with the latent factors, i.e., APOE ε4 was most strongly associated with the long fibre bundle factor and APOE ε2 was more associated with temporal-frontal factor. Our work provides insights into disease heterogeneity in brain white matter throughout the prolonged course of AD, sheds light on the association between the genotype and the disease subtype, and facilitates precision medicine.

2. Material and methods {#s0010}
=======================

2.1. Overview {#s0015}
-------------

We performed the following analyses on fractional anisotropy (FA) maps derived from DTI scans, which measure WM integrity. First, the LDA model was used to estimate the degeneration probabilities *p*(*Voxel* \| *Factor*) of each voxel in each factor, from the AD patients. Afterwards, the estimated latent factors were used to infer the factor compositions *p*(*Factor* \|*Patient*) of both AD patients and non-demented participants, including participants with early mild cognitive impairment (EMCI), late mild cognitive impairment (LMCI) and normal controls (NC). Second, we investigated whether the factor compositions are stable over 3/6/12/24 months as the disease progresses. Third, using longitudinal analyses, we explored whether different WM impairment factors are associated with memory and executive function decline differently across the prolonged course of AD. Last, we investigated whether the *APOE* genotype is associated with the disease subtype (i.e., latent factor compositions) by using a general linear model (GLM).

2.2. Data {#s0020}
---------

Data used in preparation of this article were obtained from the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu/){#ir0020}). The ADNI was launched in 2003 as a public-private partnership and led by Principle Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to examine whether structural MRI, functional MRI, DTI, PET, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early AD (up-to-date information is at [www.adni-info.org](http://www.adni-info.org){#ir0025}).

Our work was based on ADNI-2 and ADNI-GO (extracted on April 08, 2018), and enrolled all the available participants having both corrected FA images and structural MRI images of good quality. As listed in [Table 1](#t0005){ref-type="table"}, this study included 232 participants at baseline, comprised of 48 AD patients, 90 EMCI, 44 LMCI and 50 NC. These participants were longitudinally followed at 3, 6, 12, 24, 36, and 48 months later (most participants have scans at more than two time points), totalling 893 time points of 232 participants.Table 1Study demographics, cognitive scores, and imaging metrics of baseline scans.Table 1NCEMCILMCIADParticipants at baseline50904448*3 months*68%61%77%75%*6 months*74%46%66%65%*1 year*76%56%66%67%*2 years*62%56%45%13%Sex (female/male)27/2336/5417/2720/28Age (years)72.5(6.2)72.9(7.9)73.9(7.1)75.0(8.7)Education (years)16(3)[c](#tf0025){ref-type="table-fn"}16(3)16(3)15(3)Memory (z-score)[\#](#tf0005){ref-type="table-fn"}0.99(0.60)[a](#tf0015){ref-type="table-fn"}, [b](#tf0020){ref-type="table-fn"}, [c](#tf0025){ref-type="table-fn"}0.49(0.64)[d](#tf0030){ref-type="table-fn"}, [e](#tf0035){ref-type="table-fn"}−0.31(0.65)[f](#tf0040){ref-type="table-fn"}−0.92(0.50)Executive function (z-score)[\$](#tf0010){ref-type="table-fn"}0.81(0.73)[a](#tf0015){ref-type="table-fn"}, [b](#tf0020){ref-type="table-fn"}, [c](#tf0025){ref-type="table-fn"}0.19(0.74)[e](#tf0035){ref-type="table-fn"}0.14(0.77)[f](#tf0040){ref-type="table-fn"}−0.77(0.81)Intracranial vault (ICV) (cm^3^)1380(113)[b](#tf0020){ref-type="table-fn"}1406(137)1443(132)1395(158)Total gray matter (%ICV)42.4(1.2)[b](#tf0020){ref-type="table-fn"}, [c](#tf0025){ref-type="table-fn"}42.2(1.5)[d](#tf0030){ref-type="table-fn"}, [e](#tf0035){ref-type="table-fn"}41.4(1.5)[f](#tf0040){ref-type="table-fn"}40.6(1.5)*APOE* ε3/4 or 4/40.31[a](#tf0015){ref-type="table-fn"}, [b](#tf0020){ref-type="table-fn"}, [c](#tf0025){ref-type="table-fn"}0.57[d](#tf0030){ref-type="table-fn"}, [e](#tf0035){ref-type="table-fn"}0.880.82*APOE* ε2/3 or 2/20.110.110.070.07CSF Aβ~1--42~ (pg/ml)203.8(50.3)[a](#tf0015){ref-type="table-fn"}, [b](#tf0020){ref-type="table-fn"}, [c](#tf0025){ref-type="table-fn"}174.3(49.6)[e](#tf0035){ref-type="table-fn"}155.1(52.1)137.3(36.3)[^2][^3][^4][^5][^6][^7][^8][^9][^10]

The 48 AD patients at baseline were used as input of the LDA model to identify latent WM impairment factors in AD. Based on the derived latent factors, individual factor composition was inferred for every participant. With the factor composition profiles (at 893 time-points) quantified by the LDA framework, we delved into further statistical analysis to reveal the associations between latent impairment factors and cognition and *APOE* genotype.

For neuropsychological data, memory (ADNI-Mem) ([@bb0075]) and executive function (ADNI-EF) ([@bb0115]) scores were explored. For genotype data, *APOE* ε4 and *APOE* ε2 were considered. 170 participants at baseline have genotype information available, which were used to explore genotype effects on disease subtypes (i.e. latent factor compositions).

2.3. Tract-Based Spatial Statistics (TBSS) {#s0025}
------------------------------------------

DTI scans help us understand the regional basis of white matter tissue degeneration in clinical conditions. Changes in diffusion properties demonstrate distinct zones of alterations, which potentially stem from the differences of the underlying pathology. FA was considered as the primary metric of interest in this study, which is quantified by the orientational coherence of water diffusion within a voxel. FA reflects the extent of astrogliosis, myelin and axonal loss.

The FA images were analysed using TBSS ([fsl.fmrib.ox.ac.uk](http://fsl.fmrib.ox.ac.uk){#ir0030}/fsl/fslwiki/TBSS) that comes as a part of FSL ([@bb0255]). First, 232 FA images at baseline scans ([Table 1](#t0005){ref-type="table"}) were aligned into a common space by using nonlinear registration. Second, the mean FA image was generated and thinned in order to create a group\'s mean FA skeleton, representing the centre of the tracts. Every participant\'s aligned FA data was then projected onto this skeleton. Third, the log~10~ transformation was applied to the resulting skeletonized FA data. Fourth, effects of age, sex, and education on log transformed FA values were regressed out with a general linear model (GLM) estimated from 50 NC participants.

For the follow-up scans (647 time-points), the FA images went through similar TBSS procedures without generating a new WM skeleton. Instead we used the WM skeleton derived from the baseline scans as the standard WM template to derive skeletonized FA maps.

2.4. Latent Dirichlet Allocation (LDA) {#s0030}
--------------------------------------

In this study, our premise is that an individual AD patient expresses one or multiple WM impairment factors that are associated with distinct WM impairment patterns ([Fig.1](#f0005){ref-type="fig"}). The LDA method ([@bb0040]) is well suited for modelling DTI data under such a premise, which.Fig. 1Schematic illustration of impairment factor decomposition using the Latent Dirichlet Allocation (LDA) framework on brain images. (A) Given a cohort of brain images, LDA estimates group-wise latent impairment factors and each factor is associated with distinct patterns of structural impairment, represented as *p*(*Voxel* \| *Factor*). In this schematic figure, the red triangle reveals the brain region affected by latent impairment factor 1, the blue rectangle reveals impairment factor 2 and the green ellipse reveals impairment factor 3. Each voxel is associated with one or more latent impairment factors, denoted by *p*(*Factor* \|*Voxel*), as illustrated as the pie charts. (B) LDA is used to further infer *p*(*Factor* \|*Patient*), the probability that a patient expresses a particular factor. *p*(*Factor* \|*Patient*) serves as the profile of the disease subtype. As illustrated, a patient expresses one or multiple latent impairment factors was originally proposed to discover latent topics in a set of text documents. In the brain imaging scenario, each participant\'s WM image is a collection of voxels, and each voxel is associated with a subset within total *K* impairment factors; this is analogous to text analysis in that a document is collection of words, and each word is associated with a subset within total *K* latent topics. Each latent impairment factor is represented by a probability distribution over all WM voxels *p*(*Voxel* \| *Factor*), which can be visualized as a probabilistic impairment map overlaid on the FSL MNI152 FA skeleton template ([Fig.2](#f0010){ref-type="fig"}). Each AD patient expresses multiple WM impairment factors to different extents and *p*(*Factor* \|*Patient*) denotes the composition of impairment factors expressed by a patient.Fig. 1

As LDA works on discrete data, the continuous FA maps need to be discretized by mapping greater WM impairment to a larger positive integer. Specifically, FA values were first log-transformed to make data better conform to normality, and then z-transformed (with respect to NC baseline scans) for each AD patient at baseline. A *z* score below zero at a given voxel of a particular participant is an indication of degeneration relative to the NC participants. *Z* scores above zero suggest unimpaired voxels and were set to zero. The *z* scores were discretized by multiplying by −10 and rounding to the nearest integer. Larger positive values imply more severe impairment.

For a specified number *K* of WM impairment factors, LDA analysis was performed on the transformed FA images of AD patients to identify latent factors and infer factor compositions. Specifically, the probabilistic distributions *P*(*Voxel* \| *Factor*)of WM impairment, estimated from AD patients were used to infer factor compositions *P*(*Factor*\| *Patient*) of individual participants. The factor composition of a participant can be visualized as a point inside the factor space (e.g., *K* = 3 is represented by a triangle) as shown in [Fig.4](#f0020){ref-type="fig"}. The factor composition represents a subtype of AD.

Moreover, the robustness of LDA were also evaluated on two aspects (*SI Appendix)*. First, the stableness of identified latent factors across different initializations was investigated. For each *K*, the LDA algorithm was run for 20 times with random initializations. We observed that different random initializations led to almost identical solutions, suggesting that the identified latent factors are robust across different runs. The run with the highest data likelihood (indicating the model best fits the data) was selected as the optimal factor decomposition of the current *K*. Second, the spatial consistency of two sets of latent factors identified by LDA with different *K*'s was investigated. The spatial consistency of latent factors is defined as the situation that latent factors reside in approximately the same brain regions regardless of a particular *K* value. For *K* in candidate sets of {2, 3, ..., 6} ([@bb0005]), we observed that the identified latent factors were robust across different *K*'s (*SI Appendix, Fig.S1*).

2.5. Choosing the number *K* of factors {#s0035}
---------------------------------------

The number *K* of latent factors is an important parameter of LDA. To determine *K*, we proposed to maximize the spatial separation criterion, i.e., the latent factors that best represent heterogeneity are those whose spatial distributions are maximally separated or minimally overlapped. Intuitively, this criterion expects that any two latent impairment factors should affect different brain regions, so that the factors are meaningful, interpretable, and heterogeneous. To measure the spatial separation of latent factors within the *K* factor model, the correlation coefficients between all the *C*~*K*~^2^ pairs of factors were calculated, and the maximum correlation was used to obtain the degree of spatial separation defined as:$$1 - \max\limits_{\forall i,j \in {\{{1,\ldots,K}\}},i \neq j}\left( {{\text{corr}\left( {P\left( {\mathit{Voxel}\ } \right|\ \mathit{Fact}or_{i}} \right)},{\left. P\left( {\mathit{Voxel}\ } \right|\ \mathit{Facto}r_{j} \right)\left. \  \right)}} \right).$$

We first observed qualitatively how the estimated factors vary with *K* from 2 to 4 ([Fig.2](#f0010){ref-type="fig"}) and then adopted grid search to quantitatively choose the best *K* that maximize the separation of latent factors for *K* from 2 to 6. After determining *K*, LDA analysis was performed on baseline AD scans to identify latent WM impairment factors. Then, the LDA analysis inferred factor compositions for all 893 time-points of 232 participants ([Table 1](#t0005){ref-type="table"}), which were further employed in the following statistical analyses.Fig. 2Latent white matter (WM) impairment factors in AD identified by the LDA model with *K* = 3. The probabilistic impairment distribution *p*(*Voxel* \| *Factor*) of each factor was quantified and displayed on the WM skeleton. Red colour indicates brain regions that are more susceptible disease targets while blue colour indicates less susceptible regions. Three impairment factors were the temporal-frontal factor, the parietal factor, and the long fibre bundle factor.Fig. 2

The following statistical analyses were based on the LDA model with *K* = 3, which identified three latent WM impairment factors including the temporal-frontal factor *tf*, the parietal factor *p* and the long fibre bundle factor *l*.

2.6. Evaluating the longitudinal stability of latent factors {#s0040}
------------------------------------------------------------

One question naturally arises: does the latent WM impairment factors change as the disease progresses? In order to quantify the stability of latent factors, we examined participants who had both their baseline scans and follow-up scans available (3/6/12/24 months respectively). If the latent factors are stable as AD progresses, then the factor compositions of individuals should remain the same over time. To investigate the stability of the factor compositions, we drew scatter plots where each dot represents an individual with the *x* coordinate representing the composition proportion of a particular factor at baseline and the *y* coordinate representing the corresponding factor composition proportion after 12 months ([Fig.5](#f0025){ref-type="fig"}, *SI Appendix, Table S1 and Fig.S6*). A linear relationship with a slope close to 1 in the scatter plot would indicate stable the WM impairment factor over the disease progression.

2.7. Modelling the longitudinal cognitive decline using latent WM impairment factors {#s0045}
------------------------------------------------------------------------------------

Here we attempt to decouple the associations between WM impairment factors and cognitive decline in AD. Relating to memory and executive function, we asked two questions: (i) whether the WM impairment factors correspond to the same baseline cognitive scores and the decline rates throughout the disease course; and (ii) when modelling the longitudinal decline, whether the latent factors lead to higher sensitivity compared to the traditional modelling approach.

Accordingly, linear mixed effect (LME) models ([@bb0035]) were used to answer the two questions. For the first question, the response variable *y* of the LME model consisted of the longitudinal ADNI-Mem (508 time-points) and ADNI-EF scores respectively (504 time-points, as described in [Table 1](#t0005){ref-type="table"}). The explanatory fixed-effects variables included: (i) mean FA values on impaired regions *FA* (*SI Appendix)* indicating the severity of WM impairment; (ii) factor compositions indicating the subtype, i.e., the compositions of parietal factor *p* and the long fibre bundle factor *l* (the composition of temporal-frontal factor *tf* is implicit in *p* + *l* + *tf* = 1); (iii) elapsed time *t* from the baseline; (iv) interactions between factor compositions and time from baseline, i.e. *p* · *t* and *l* · *t*; and (v) nuisance variables, including amyloid *x*~1~, sex *x*~2~, education *x*~3~ and gray matter volume *x*~4~ (age and white matter volume were not significant associated with cognition as evaluated by ANOVA). The resulting LME model, denoted as *M*, is given by$$y = \left( {\beta_{0} + \beta_{\mathit{FA}} \cdot \mathit{FA} + \beta_{p} \cdot p + \beta_{l} \cdot l} \right) + \left( {\beta_{t0} + \beta_{\mathit{tp}} \cdot p + \beta_{\mathit{tl}} \cdot l} \right) \cdot t + \beta_{1}x_{1} + \beta_{2}x_{2} + \beta_{3}x_{3} + \beta_{4}x_{4} + \varepsilon,$$where *y* denotes the ADNI-Mem/ADNI-EF score, ε is the residual, and *β*~∗~ indicate the regression coefficients. As to interpret the LME model, *β*~0~ + *β*~*p*~reflects the parietal factor\'s baseline cognitive score,*β*~*t*0~reflects the temporal-frontal factor\'s decline rate, and *β*~*t*0~ + *β*~*tp*~ reflects the parietal factor\'s decline rate. We aimed to investigate whether the three WM impairment factors have the same baseline cognitive scores and decline rates through the disease course. Accordingly, as for hypothesis tests, we could ask whether the temporal-frontal factor have significantly stronger effect on ADNI-Mem than the long fibre bundle factor, and whether the parietal factor and the temporal-frontal factor equally affect the decline rate of ADNI-EF throughout the disease stages. The results of the statistical tests are shown in [Table 2](#t0010){ref-type="table"}.Table 2Comparison of baseline scores and decline rates of (A) executive function and (B) memory across factors.Table 2**(A) ADNI - executive function(B) ADNI --memory***p* − *tfl* − *tfl* − *pp* − *tfl* − *tfl* − *p*Baseline score−0.84 (0.37) **p = 0.02**- 0.09 (0.37) *p* = 0.81+0.75 (0.37) *p* = 0.052- 0.07 (0.36) *p* = 0.84−0.13 (0.36) *p* = 0.73−0.05 (0.36) *p* = 0.89Decline rate+0.15 (0.11) *p* = 0.15+ 0.39 (0.15) ***p*** = **0.009**+0.23 (0.14) *p* = 0.08^\$^- 0.05 (0.08) *p* = 0.56+0.14 (0.12) *p* = 0.24+0.19 (0.10) *p* = 0.07^\$^[^11]

To compare our model with the traditional model and demonstrate the predictive power of the latent factor compositions, we compared our model *M* with the traditional model that simply deploys the traditional measures without factoring the compositions (or into subtypes). A traditional model, denoted as *M*~*classic*~, would be$$y = \beta_{0} + \beta_{\mathit{FA}} \cdot \mathit{FA} + \beta_{t0} \cdot t + \beta_{1}x_{1} + \beta_{2}x_{2} + \beta_{3}x_{3} + \beta_{4}x_{4} + \varepsilon,$$

The ANOVA analyses was performed to evaluate *M* and *M*~*classic*~, respectively, in predicting memory and executive function.

2.8. Association of *APOE* genotype with WM impairment factors {#s0050}
--------------------------------------------------------------

We investigated whether *APOE* genotype, as a well-known genetic risk factor, was associated with the disease subtype. More specifically, participants with different genotypes might have different associations with the latent impairment factors. To test this hypothesis, we performed an analysis with a GLM model, including the following fixed-effects variables: (i) binary group indicators, i.e., the EMCI group *em*, the LMCI group *lm* and the AD group *ad* (the NC group is implicit); and (ii) factor compositions, i.e., the parietal factor *p* and the long fibre bundle factor *l* (the temporal-frontal factor *tf* is implicit in *tf* + *p* + *l* = 1). The resulting GLM model is given by$$y = \beta_{0} + \beta_{\mathit{em}} \cdot \mathit{em} + \beta_{\mathit{lm}} \cdot \mathit{lm} + \beta_{\mathit{ad}} \cdot \mathit{ad} + \beta_{p}p + \beta_{l}l + \varepsilon,$$where *y* denotes the *APOE ε*4/*ε*2 carrier status (0, 1 carrier or 2 carriers), *β*~∗~ indicate the regression coefficients, and ε is the residual. Note that *β*~*p*~ captures the difference between the responses of the parietal factor *p* and the temporal-frontal factor *tf*, and *β*~*l*~ captures the difference between the responses of the long fibre bundle factor *l* and temporal factor *tf*.

In order to compare the association between the genetic status and different factors, we further tested the null hypothesis *H*~0~ : *Cβ* = 0, where *β* = \[*β*~0~, *β*~*em*~, *β*~*lm*~, *β*~*ad*~, *β*~*p*~, *β*~*l*~\]^*T*^and *C* denotes the linear contrast corresponding to a particular scientific question. For example, to test the differences between all factors, we chose *C* = \[0, 0, 0, 0, 1, 0; 0, 0, 0, 0, 01\]; for differences between the parietal factor *p* and the long fibre bundle factor *l*, we choose *C* = \[0, 0, 0, 0, 1, −1\]. The results of the statistical tests are shown in [Table 3](#t0015){ref-type="table"}.Table 3Comparison of effects of APOE ε4 and APOE ε2 on different latent factors.Table 3**(A) APOE ε4(B) APOE ε2***p* − *tfl* − *tfl* − *pp* − *tfl* − *tfl* − *p*+0.19 (0.23) *p* = 0.42+ 1.1 (0.28) ***p* = 0.0001**+ 0.91 (0.25) ***p* = 0.0006**- 0.26 (0.12) ***p* = 0.02**−0.15 (0.14) *p* = 0.28−0.11 (0.13) *p* = 0.39[^12]

2.9. Implementation details {#s0055}
---------------------------

For LDA analysis, we used the VEM implementation ([www.cs.princeton.edu/\~blei/lda-c/](http://www.cs.princeton.edu/~blei/lda-c/){#ir0035}) and for the LME analysis, the LME toolbox was used ([github.com/NeuroStats/lme](https://github.com/NeuroStats/lme){#ir0040}). The code for identifying the coherence of the WM impairment factors was adapted from ([github.com/ThomasYeoLab/CBIG](http://github.com/ThomasYeoLab/CBIG){#ir0045}). We used nilearn ([nilearn.github.io](http://nilearn.github.io){#ir0050}) to visualize WM impairment factors, and ggplot2 ([www.ggplot2.org](http://www.ggplot2.org){#ir0055}) and ggtern ([www.ggtern.com](http://www.ggtern.com/){#ir0060}) for visualizing factor compositions. The code and intermediate results will be released on GitHub ([github.com/xiuchao/ldaFA](https://github.com/xiuchao/ldaFA){#ir0065}).

3. Results {#s0060}
==========

3.1. Overall approach {#s0065}
---------------------

Our study consisted of the following parts: (i) identifying multiple WM impairment factors in AD patients and inferring factor compositions of individual participants (both AD and non-AD) by using LDA; (ii) exploring the stability of latent factors as the disease progresses; (iii) examining the associations between WM impairment factors and cognition (i.e. ADNI-Mem and ADNI-EF); and (iv) examining the association between the genotype (*APOE ε*4/*ε*2) and the disease subtype (i.e. factor compositions). The details of the results are described as follows.

3.2. WM impairment factors in AD {#s0070}
--------------------------------

We hypothesized that AD patients express one or more WM impairment factors and this hypothesis can be captured by the LDA model ([Fig.1](#f0005){ref-type="fig"}). For the 48 AD patients at baseline, given the pre-processed FA skeleton maps and the number of *K* factors, the LDA method estimated the probability distribution of each impairment factor *p*(*Voxel* \| *Factor*) and the factor composition *p*(*Factor* \|*Patient*) of individual participant.

The number of impairment factors *K* is a free parameter in the LDA model*.* We first qualitatively inspected how the estimated factors *p*(*Voxel* \| *Factor*) changed as *K* was varied from 2 to 4. The impairment factors were spatially consistent (*Section 2.3*) for all *K* = 2 to 4 ([Fig.2](#f0010){ref-type="fig"}). Specifically, the *K* = 2 model revealed an impairment factor throughout cortical regions, which included temporal regions (para-hippocampal WM and temporal WM), frontal and parietal WM, and another long fibre bundle factor that spreads over corpus callosum and superior longitudinal fasciculus (SLF). The *K* = 3 model revealed a similar long fibre bundle factor, whereas the cortical factor split into a parietal factor with WM impairment mainly in parietal lobe and a temporal-frontal factor associated with extensive WM impairment in para-hippocampus gyrus, temporal lobe and frontal lobe. The *K* = 4 model revealed three latent factors similar with the *K* = 3 model, as well as a redundant factor that spanned over the brain regions identified by the other three factors. A closer inspection revealed that the redundant factor was a mixture of the other three factors, and thus did not provide any new insight into susceptible WM tissues. In addition, when *K* further increased, more redundant factors were observed. To summarize, the latent impairment factors were spatially consistent as *K* was varied ([Fig.2](#f0010){ref-type="fig"}, *Fig.S1*); whereas redundant factors appeared when *K* increased from 3 to 4 or more.

We further quantitatively evaluated the spatial separation among individual latent factors within each LDA model of a particular *K*. As visually seen in [Fig.3](#f0015){ref-type="fig"}, *K* = 3 achieved the largest spatial separation between latent factors. Therefore, *K* = 3 was selected as the best number of latent factors on this data. Notably, our findings are consistent with previous AD subtype studies in terms of the number of subtypes. For example, Murray\'s study revealed three AD subtypes, which is based on neuropathologcial evidence ([@bb0200]). In addition, other previous studies based on structural MRI also reported three distinct patterns of GM atrophy ([@bb0310]; [@bb0205]) and NFT changes ([@bb0290]).Fig. 3The degree of spatial separation among latent factors changes with respect to *K*, the number of factors. *K* = 3 achieves the highest separation among latent factors.Fig. 3

In addition, among the 48 AD patients, 38 had their cerebrospinal fluid (CSF) amyloid data available and 35 of 38 patients were Aβ + (CSF amyloid concentration \< 192 pg/mL). We performed LDA on the 35 Aβ + AD dementia patients alone and compared the WM impairment factors with those derived using all 48 AD patients (*SI Appendix Fig.S2*). The WM impairment factors obtained under the two settings (48 AD vs. 35 Aβ + AD) were almost identical, with an average correlation *r* = 0.95. Considering such a high similarity, we used the factors derived from the larger sample for further analysis.

3.3. The stability of latent factors as AD progresses {#s0075}
-----------------------------------------------------

The probabilistic WM impairment distributions *p*(*Voxel* \| *Factor*) estimated from the AD patients were used to infer factor compositions *p*(*Factor* \|*Patient*) of the non-demented participants, including EMCI, LMCI and NC, by using the variational expectation-maximization (VEM) LDA algorithm ([@bb0040]). As shown in [Fig.4](#f0020){ref-type="fig"}, most of the participants expressed multiple WM impairment factors instead of a single predominant factor. It is worth noting that NC participants were more homogeneous (i.e., clustered close to each other), while AD patients were more heterogeneous.Fig. 4Factor compositions of participants at baseline. Each dot corresponds to a participant and its location represents his/her factor composition. Corners of this triangle represent pure factors; a closer distance to a corner indicates a higher probability to the respective factor. As can be seen, most participants express multiple factors, and NC participants are clustered more closely than AD patients, indicating the heterogeneity of AD.Fig. 4

To investigate whether the expression of impairment factors changed over the progression of AD, we compared the factor compositions of participants who had both the baseline scan and the 12-month follow-up scan available. As shown in [Fig.5](#f0025){ref-type="fig"}, the factor probabilities were highly consistent (*r* \> 0.96 across all the three factors), indicating that the factor compositions remained stable over the disease progression (for time-points at 3/6/24 months, see *SI Appendix Table S1*). This result is in accordance with earlier study on GM, which reported that the atrophy factor compositions were stable after two years ([@bb0310]). This finding further supports that the impairment factors represents different impairment subtypes instead of different disease stages.Fig. 5Stability of factor compositions of the three factors over 12 months. Each dot represents a participant, of which the *x* and *y* axes represent the probabilities of factors at the baseline and at 12 months later, respectively. Linear fits to the scatters are close to the *y* = *x* line with correlations *r* \> 0.96 for all the three impairment factors, suggesting that the factor compositions are stable during disease progression.Fig. 5

3.4. Association between WM impairment factors and cognition {#s0080}
------------------------------------------------------------

For memory (ADNI-Mem) and executive function (ADNI-EF), we investigated whether distinct WM impairment factors were associated with the same baseline scores and decline rate as the disease progressed.

First, diagnostic groups differed in cognition as expected ([Table 1](#t0005){ref-type="table"}). ADNI-Mem was significantly lower in each diagnostic group (NC \> EMCI\>LMCI\>AD, *p* \< 0.05) while ADNI-EF followed similar pattern (NC \> EMCI = LMCI\>AD, *p* \< 0.05).

Second, an LME model was used to relate longitudinal cognitive scores (ADNI-Mem/ADNI-EF) with the observed predictors, including the mean FA of impaired brain regions (*SI Appendix*), the factor compositions, the progression time, and interactions between time and factor compositions (*Method 2.6*). We studied whether each factor had the same baseline cognition and decline rate through the disease course. For EF ([Table 2](#t0010){ref-type="table"}A), the temporal-frontal factor was more associated with baseline EF compared with the parietal factor (*p* = 0.02); the long fibre bundle factor was significantly more associated with the EF decline rate compared with the temporal-frontal factor (*p* = 0.009), and tended to be more associated with the EF decline rate than the parietal factor (*p* = 0.08). For memory ([Table 2](#t0010){ref-type="table"}B), the three factors were almost equally associated with baseline memory and decline rate across the disease spectrum. The long fibre bundle factor tended to be more associated with memory decline rate than the parietal factor in AD patients (*p* = 0.07). Our findings suggest that latent factors have distinct effects on different cognitive domains.

Third, we evaluated whether incorporating factor compositions could lead to better modelling of longitudinal effects on cognition. ANOVA analysis was performed to compare the latent factor based model *M* and the traditional model *M*~*classic*~ in distinct cognitive domains. We found that the latent factor compositions significantly contributed to better prediction of EF (*p* = 0.01) while had no significant effect on memory prediction (*p* = 0.48). These results comply with the aforementioned findings (in [Table 2](#t0010){ref-type="table"}) and show that by enrolling subtype information (through latent factor composition), longitudinal changes can be predicted with higher sensitivity in specific cognition domains.

3.5. Association between APOE genotype and latent factors {#s0085}
---------------------------------------------------------

The *APOE* genotype has been identified as genetic susceptibility factor in AD ([@bb0100]; [@bb0095]). We investigated whether the *APOE* genotype has different effects on different white matter impairment factors by using a GLM model *(Method 2.7)*. As summarized in [Table 3](#t0015){ref-type="table"}A, the long fibre bundle factor was more associated with *APOE* ε4 than the temporal-frontal (*p* = 0.0001) and the parietal factor (*p* = 0.0006). As summarized in [Table 3](#t0015){ref-type="table"}B, the temporal-frontal factor was more associated with APOE ε2 than the parietal factor (*p* = 0.02). Our findings suggest that the genotype affects the disease subtype (i.e. factor compositions) differently.

4. Discussion {#s0090}
=============

In this work, instead of assuming an overall disease effect on WM impairment, we identified distinct latent impairment factors in AD patients by using LDA modelling of DTI data ([Fig.1](#f0005){ref-type="fig"}). Three latent impairment factors were revealed in AD ([Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}). Each participant was allowed to exhibit their own unique factor compositions ([Fig.4](#f0020){ref-type="fig"}) under the LDA framework, which were found to be stable across stages ([Fig.5](#f0025){ref-type="fig"}). These impairment factors deteriorated longitudinal memory and executive function differently along the full disease course of AD ([Table 2](#t0010){ref-type="table"}). Moreover, *APOE* genotype has distinct effects on different WM impairment factors ([Table 3](#t0015){ref-type="table"}). To summarize, our work suggests that the heterogeneity of WM impairment in AD patients are associated with the variance in longitudinal cognitive decline and *APOE* genotype is associated with latent factors. In summary, this work revealed the links between WM impairment factors, *APOE* genotype, and cognition in distinct domains.

4.1. WM impairment factors in AD {#s0095}
--------------------------------

*K* = 3 model achieved the largest dissociation between factors within each LDA model and the three impairment factors were investigated in this study. Earlier studies have consistently reported three subtypes in AD ([@bb0200]; [@bb0310]; [@bb0205]; [@bb0215]). Our three-factor model includes a temporal-frontal factor, a parietal factor, and a long fibre bundle factor ([Fig.2](#f0010){ref-type="fig"}). Specifically, we observed that the temporal-frontal factor was linked with WM impairment in hippocampus, parahippocampus, medial temporal lobe and frontal lobe. Earlier work demonstrated that changes in parahippocampal region may result in isolation of the hippocampus, which contribute to impairment in memory ([@bb0230]); The frontal lobe regions have been suggested to associate with executive function ([@bb0260]; [@bb0050]). The parietal factor was associated with the impairment in precuneus and parietal lobe. The precuneus has been associated with retrieval of episodic memory and self-processing operations ([@bb0250]; [@bb0195]; [@bb0150]). The long fibre bundle factor was associated with the WM impairment in splenium and the body of corpus callosum (CC) and SLF. The splenium of CC predominantly connects the temporal lobe and the occipital lobe between the two hemispheres. The SLF is an association fibre tract that contains three separate components ([@bb0190]). SLF II (Table S2), the major component of SLF, connects the caudal-inferior parietal cortex and dorsolateral prefrontal cortex, and serves to transmit working memory in the prefrontal cortex to provide the parietal cortex with information to regulate spatial attention and retrieval of spatial information ([@bb0080]).

Accumulating evidence suggests that structural and histological changes in AD are heterogeneous. For example, heterogeneity in cortical atrophy has been evinced by using structural MRI ([@bb0310]; [@bb0205]; [@bb0215]) and heterogeneity in NFT distributions has been demonstrated from thioflavinS fluorescent microscopy ([@bb0200]). While a few studies have investigated the heterogeneous white matter alterations in AD, using DTI data ([@bb0125]; [@bb0025]), to our best knowledge, this is the first study that employ latent factor decomposition on white matter impairment to profile subtypes of AD. By referring to the field knowledge, we can interpret a particular WM impairment factor and how it may be associated with various cognitive domains. However, it is hard to make direct comparison with earlier subtype studies which were mostly based on GM atrophy. We could see rough spatial correspondence between WM impairment factors and GM atrophy factors identified in earlier studies. For example, a recent GM atrophy study identified three subtypes: the parietal predominant subtype that roughly correspond to our parietal WM impairment factor, the medial temporal predominant subtype that roughly correspond to our temporal-frontal factor, and the diffuse atrophy subtype that roughly corresponds to the long fibre bundle factor ([@bb0215]). Yet such correspondence is not strict due to the tissue difference and should be interpreted with caution. Secondary degeneration of WM, as a result of cortical atrophy, may contribute to the observed rough spatial correspondence. Furthermore, we identified GM atrophy factors based on the structural MRI data of the same dataset (SI Appendix, *Fig.S5*), which also showed no exact one-to-one correspondence with the WM impairment factors. This further illustrates that despite partly as a secondary effect of cortical atrophy, WM impairment still provides unique information on AD. Previous study on ADNI dataset also testified that DTI provides unique information about cognition instead of merely recapitulations of established association between other biomarkers of AD (e.G. *hippocampus* volume) ([@bb0245]). Accordingly, WM impairment factors uniquely contribute to portraying subtypes of AD. As future work, one can probe AD subtypes by simultaneously considering GM atrophy and WM impairment.

4.2. Factor compositions were stable as the disease progresses {#s0100}
--------------------------------------------------------------

The LDA method in the Bayesian framework treats AD cases as entities with mixed membership of one or multiple factors, and allows each participant to exhibit his/her own unique factor composition. For a hypothetical patient, his/her factor composition profile could be portrayed as expressing 60% the temporal-frontal factor, 20% the parietal factor and 10% the long fibre bundle factor. Such probabilistic factor composition extends previous approaches that classified patients into distinct subtypes ([@bb0290]; [@bb0060]), and makes it more feasible to study how the heterogeneity of WM impairment was associated with variance in cognitive decline in distinct cognition domain. However, a natural question arises: was the observed heterogeneity attributed to disease stages, or disease expressions, i.e., subtypes ([@bb0220]; [@bb0305])?

To address this question, we investigated whether that factor compositions were stable after 3/6/12 months ([Fig.5](#f0025){ref-type="fig"}, *SI Appendix, Table S1 and Fig.S6*). If the disease stages hypothesis stands, a hypothetical individual would express more cortical factor after 12 months, which is not supported by our results. As the factor compositions were stable as the disease progresses, we can conclude that the heterogeneity in WM degeneration is primarily due to the disease subtypes. Our result complies with an earlier AD subtype study that reported stable GM atrophy factor across disease stages ([@bb0310]).

4.3. Factors reflect distinct association with longitudinal cognitive decline {#s0105}
-----------------------------------------------------------------------------

Our work revealed that distinct WM impairment factors were associated with different cognition domains differently as the disease progressed ([Table 2](#t0010){ref-type="table"}).

Executive function includes higher-order cognitive processes such as shifting attention, cognitive flexibility, cognitive fluency, working memory, planning and organization. The temporal-frontal factor showed more association with baseline EF compared with the parietal factor. This finding was in line with earlier work that reported that frontal lobe brain regions were associated with executive function ([@bb0260]; [@bb0050]), and the frontal-parietal network has been implicated in facilitating the integration and control of executive processes ([@bb0020]). The long fibre bundle factor was more associated with EF decline rate compared with the temporal-frontal factor (*p* = 0.009), and was inclined to be more associated with EF decline rate than the parietal factor (*p* = 0.08). By looking into the long fibre bundle factor, the largest commissural tract CC predominantly connects the temporal lobe and the occipital lobe between the two hemispheres; the association fibre tract SLF connects the caudal-inferior parietal cortex and dorsolateral prefrontal cortex. The prior knowledge that CC and SLF serve to transmit working memory in the prefrontal cortex and to provide the parietal cortex with information for regulating spatial attention and retrieval of spatial information ([@bb0080]), partially supports our discovery that the long fibre bundle factor was most associated with to EF decline rate in AD.

For memory, the three factors contribute equally to the memory decline in each group. Also, as illustrated in *Section 4.1*, the temporal-frontal factor involve WM in hippocampus and temporal lobe, the most well-known brain regions related with memory ([@bb0230]); the parietal factor includes the precuneus and parietal lobe WM that is related with episodic memory retrieval ([@bb0250]; [@bb0195]; [@bb0150]); the long fibre bundle factor includes CC and SLF, which are related with visual memory ([@bb0080]; [@bb0270]). We can assume that the three factors are all associated with memory decline, yet further studies are necessary to examine whether a dominant factor exists by using a larger data set.

Concerning previous DTI studies on the same ADNI dataset, though cross-sectional studies ([@bb0130]; [@bb0030]) showed the association between WM impairment measured by DTI metrics and executive function decline, yet longitudinal study ([@bb0245]) suggested the insensitivity of DTI metrics to reveal the changing rate of cognitive decline. Our study, based on the same dataset, revealed that the long fibre bundle factor was more associated with EF decline rate than the other two latent WM impairment factors. Our findings suggested that by differentiating the subtypes of AD, we could achieve a finer view in interpreting the data. Our work corresponds with earlier cross-sectional studies ([@bb0130]; [@bb0030]) and expands the longitudinal study ([@bb0245]) by illustrating the effect of latent factors on longitudinal cognitive decline of multi-domain.

4.4. *APOE* genotype was associated with latent factors {#s0110}
-------------------------------------------------------

Since disease subtypes may have genetic origins, we investigated whether risk genes are associated with latent impairment factors. *APOE* has been the best-established genetic risk factor, which associated with structural and functional changes in the elderly and AD patients ([@bb0100]; [@bb0095]). The major role of apoE protein in the brain is to transport lipid components that facilitate the shaping of the myelin sheath ([@bb0180]; [@bb0135]), thus affecting WM integrity ([@bb0140]). In this study, we found *APOE* ε4 was most associated with the long-fibre bundle factor, while *APOE* ε2 was more associated with the temporal-frontal factor compared with the parietal factor ([Table 3](#t0015){ref-type="table"}). Our work lends support to the hypothesis that the *APOE* genotype modulates the phenotype of AD through influences on specific large-scale brain networks ([@bb0300]).

Revisiting the discoveries in LME analysis, the baseline executive function was more associated with temporal-frontal factor compared with the parietal factor, while *APOE* ε2 was also more associated temporal-frontal factor compared with the parietal factor ([Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}). In addition, the EF decline rate was most associated with the long fibre bundle factor, while *APOE* ε4 was also most associated with the long fibre bundle factor. Such consistency suggested that our work moved one more step towards dissociating the links between gene, brain structure and cognition. More inspiringly, assume a hypothetical patient with *APOE* ε4/ε4 (two ε4 alleles), we could expect a higher chance of expressing more long fibre bundle factor and faster EF decline. Similarly, a hypothetical patient with APOE ε2/ε2 (two ε2 alleles) could expect a higher chance of expressing more temporal-frontal factor compared with the parietal factor, as well as higher baseline EF scores.

To summarize, variation in genotypes of patients were associated with expressions of WM impairment factors (i.e., subtypes), which would manifest in features of cognitive decline. By looking such association, we could take one-step forward to precision medicine.

4.5. Limitations {#s0115}
----------------

AD dementia is a heterogeneous disease in that the origins and spread of the disease may differ substantially between different subtypes. Earlier work explored the subtypes, using neurological scores ([@bb0275]), the distribution of neurofibrillary tangles ([@bb0200]), and cortical atrophy ([@bb0310]; [@bb0205]; [@bb0215]). Along this line of research, our work demonstrated that the patterns of WM impairment could also be used to portray AD subtypes. The probabilistic profiles of subtypes, portrayed in the LDA framework, were associated with distinct trajectories of cognitive decline and may originate from different genotypes. However, there are limitations of our work.

First, the pathological basis of these WM impairment factors is still obscure. A recent study suggested that myelin and oligodxendrocytes are especially vulnerable to amyloid pathology ([@bb0085]). Further studies are needed to address the characterisation of AD subtypes using other biomarkers, e.g. white matter hyper-intensity, amyloid and tau immunohistochemistry, which may lead to a better understanding of AD heterogeneity and further facilitate early diagnosis and the monitoring of AD progression ([@bb0105]; [@bb0065]).

Second, pathological findings from autopsied cases provide the golden standard for revealing structural heterogeneity as such studies represent advanced stages of AD. However, for degeneration at the early disease stages, we have been unable to find a well-recognized reference to evaluate the structural heterogeneity findings. In addition, it is hard to make direct comparisons between neuropathologically defined subtypes, GM atrophy defined subtypes and WM impairment defined subtypes, especially as these observations were based on different participants and different analysis protocols. For this study, we presented our subtype observations on DTI data under the LDA framework, which could serve as a reference for clinicians and pathologist to unveil the broader picture of subtypes in AD.

Third, to simplify the analysis pipeline and increase reproducibility of this study, we used preprocessed images by ADNI where the corrected FA images provided the largest sample set. Therefore, we used FA measure for this study. As an initial trial to probe subtypes using DTI, this work has ignored other DTI metrics that characterize the same underlying microstructures from different aspects. For example, mean diffusivity (MD) was used as widely as FA to map white matter changes in AD; radial diffusivity, and axonal diffusivity gained more popularity as DTI markers of axonal and myeline damage, respectively ([@bb0010]; [@bb0295]). Moreover, though FA has been widely used, it was suggested that FA does not always correlate well with the actual individual fibre anisotropy and maybe sub-optimal in detecting disease processes that affect myelination ([@bb0170]). Future subtyping studies based on DTI may benefit from looking into other diffusion measures that provide more information in the diffusion profile. Moreover, as a previous study ([@bb0155]) suggested, joint analysis of the diffusion measures could be more powerful in characterizing histopathology and provide information about disease progresses not available through examination of any measure in isolation. Future DTI studies may benefit from such multivariate method for joint analysis of diffusion measures.

Finally, our study utilized the DTI images of ADNI-GO and ADNI-2 dataset, in which the enrolled patients were followed up for no \>5 years. As ADNI is still collecting more longitudinal data, future studies may benefit from enriched data resources and yield more statistically reliable analytical results. Also, as a study based on DTI data, this study has limitations inherent in DTI. More advanced imaging and modelling techniques, such as high-angular resolution diffusion imaging (HARDI), can resolve more complex diffusion geometries and further facilitate finer portrait of regional tissue impairment that would lead to more accurate subtype profiles.

5. Conclusions {#s0120}
==============

By identifying latent WM impairment factors with LDA, our work lends support to the growing belief that AD is heterogeneous rather than a single disease entity. We identified three impairment factors: the temporal-frontal factor, the parietal factor and the long fibre bundle factor. These factors were associated with distinct decline trajectories of memory and executive function across the full course of AD. Moreover, individual participant could express multiple WM impairment factors to different degrees. The heterogeneous factor compositions among participants were associated with different genotypes and can facilitate predicting individual-level cognition and contribute to precision medicine.
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[^1]: Data used in the preparation of this article were obtained from the ADNI database ([adni.loni.usc.edu](http://adni.loni.usc.edu){#ir0010}). A complete list of the ADNI investigators can be found at

    <http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf>.

[^2]: The list of participants (*N* = 232, data-points = 893) is available at [github.com/xiuchao/ldaFA](https://github.com/xiuchao/ldaFA){#ir0005}.

[^3]: ADNI-EF is available for 679 time-points, among which 504 have amyloid information available;

[^4]: ADNI-Mem is available for 691 time-points, among which 508 have amyloid information available;

[^5]: NC v. EMCI (*p* \< 0.05)

[^6]: NC v. LMCI (*p* \< 0.05).

[^7]: NC v. AD (*p* \< 0.05).

[^8]: EMCI v. LMCI (*p* \< 0.05)

[^9]: EMCI v.AD (*p* \< 0.05).

[^10]: LMCI v. AD (*p* \< 0.05).

[^11]: *tf* denotes the temporal-frontal factor, *p* the parietal factor, and *l* the long fibre bundle factor. For example, the second row suggests that participants expressing more temporal-frontal factor has higher baseline executive function than those expressing more long-fibre bundle factor. Significant comparisons are highlighted in bold.

[^12]: *tf* denotes the temporal-frontal factor, *p* the parietal factor, and *l* the long fibre bundle factor. Significant comparisons are highlighted in bold.
